Research News

Research News Image

First-Ever Drug for Postpartum Depression Approved Thirty Years After Groundbreaking Discovery

Mar 19 2019
Approximately 1 in 9 women in the United States experiences symptoms of postpartum depression (PPD). Fortunately, research uncovered the biological causes of PPD and lead to the development of a specific treatment. As one part of a major research project funded by the National Institute of Mental Health in the 1980s, researchers discovered that the hormone metabolite allopregnanolone interacts with the neurotransmitter GABA to trigger the symptoms of PPD. After years of further study and clinical trials, the FDA has approved Zulresso (brexanolone), the first-ever drug to specifically treat postpartum depression. To learn more, please visit the NIMH website.